Can a simple blood test guide kidney transplant patients to fewer drugs?
NCT ID NCT04786067
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looked at 25 kidney transplant patients to see if a blood test measuring donor DNA could help them safely reduce their immunosuppressant medications to just one drug, belatacept. The goal was to see if this approach could prevent kidney rejection while simplifying treatment. Patients were monitored for rejection and other outcomes over 12 to 36 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belatacept
- What this could lead to
- If successful, this could allow some kidney transplant patients to take fewer immunosuppressant drugs, reducing side effects and simplifying their daily routine.
- What could go wrong
- This is a small, early-phase study with only 25 participants. The main risk is that reducing immunosuppression may lead to kidney rejection, which could damage the transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT IMMUNOSUPPRESSION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.